January 11th, 2024
Investigator-initiated Phase I BNCT clinical trial for newly diagnosed glioblastoma
We would like to announce that Phase I clinical trial for newly diagnosed gliob……
Press Release
December 13th, 2023
Stella Pharma, Mitsubishi Chemical Group, and the University of Tokyo conclude Joint Research Agreement—Accelerating practical application of polyvinyl alcohol (PVA) for boron neutron capture therapy (BNCT)—
Stella Pharma Corporation , Mitsubishi Chemical Corporation of the Mitsubishi C……
June 24th, 2022
Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China
Sumitomo Heavy Industries, Ltd. and STELLA PHARMA CORPORATION have respectively……
May 19th, 2020
STELLA PHARMA will launch Steboronine®, the World’s First BNCT Drug, on May 20, 2020
STELLA PHARMA CORPORATION (Head office: Chuoku, Osaka City; President: Tomoyuki……
March 25th, 2020
STELLA PHARMA Receives Marketing and Manufacturing Approval in Japan for “Steboronine® Intravenous Drip Bag 9000mg/300mL
STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City, President: Tomoyuk……
January 23rd, 2020
How to keep boron inside cells during radiotherapy: a simple novel approach to cancer treatment
Boron neutron capture therapy (BNCT) is a technique in which p‐boronophenylalan……
November 7th, 2019
“Commencement of Clinical Trial of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma and Angiosarcoma” issued
Cancer Intelligence Care Systems, Inc. (“CICS;” President: Tetsuya Furukawa; he……
October 15th, 2019
STELLA PHARMA CORPORATION has recently filed for approval to manufacture and sell a boron agent for BNCT
STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City; President: Tomoyuk……
